Meningitis-associated hearing loss: Protection by adjunctive antioxidant therapy

Annals of Neurology

Volumn 54, Issue 4, 2003, Pages 451-458

  Klein, Matthias ^b   Koedel, Uwe ^b   Pfister, Hans Walter ^a   Kastenbauer, Stefan ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; CEFTRIAXONE; DEXAMETHASONE; MANGANESE TETRAKIS(4 BENZOIC ACID) PORPHYRIN; PLACEBO; PORPHYRIN DERIVATIVE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUDIOMETRY; BACTERIAL MENINGITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; HEARING; HEARING LOSS; INCIDENCE; MALE; MENINGITIS; NERVE CELL DEGENERATION; NONHUMAN; PERILYMPH; PRIORITY JOURNAL; RAT; SPIRAL GANGLION; STREPTOCOCCUS PNEUMONIAE;

ACETYLCYSTEINE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIOXIDANTS; AUDIOMETRY; CEFTRIAXONE; CELL COUNT; COCHLEA; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; EVANS BLUE; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; HEARING LOSS; LABYRINTHITIS; MALE; MENINGITIS, PNEUMOCOCCAL; METALLOPORPHYRINS; PEROXYNITROUS ACID; RATS; RATS, WISTAR; SPIRAL GANGLION; TIME FACTORS;

EID: 0141870088     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10684     Document Type: Article

References (39)

1. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997;337:970-976.
2. Dodge PR, Davis H, Feigin RD, et al. Prospective evaluation of hearing impairment as a sequela of acute bacterial meningitis. N Engl J Med 1984;311:869-874.
3. Arditi M, Mason EO Jr, Bradley JS, et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics 1998;102: 1087-1097.
4. Vienny H, Despland PA, Lutschg J, et al. Early diagnosis and evolution of deafness in childhood bacterial meningitis: a study using brainstem auditory evoked potentials. Pediatrics 1984;73: 579-586.
5. Merchant SN, Gopen Q. A human temporal bone study of acute bacterial meningogenic labyrinthitis. Am J Otol 1996;17: 375-385.
6. McIntyre PB, Berkey CS, King SM, et al. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA 1997;278: 925-931.
7. de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002;347:1549-1556.
8. Molyneux EM, Walsh AL, Forsyth H, et al. Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet 2002;360:211-218.
9. Rodriguez AF, Kaplan SL, Hawkins EP, Mason EO. Hematogenous pneumococcal meningitis in the infant rat: description of a model. J Infect Dis 1991;164:1207-1209.
10. Bhatt S, Halpin C, Hsu W, et al. Hearing loss and pneumococcal meningitis: an animal model. Laryngoscope 1991;101: 1285-1292.
11. Bhatt SM, Lauretano A, Cabellos C, et al. Progression of hearing loss in experimental pneumococcal meningitis: correlation with cerebrospinal fluid cytochemistry. J Infect Dis 1993;167: 675-683.
12. Osborne MP, Comis SD, Tarlow MJ, Stephen J. The cochlear lesion in experimental bacterial meningitis of the rabbit. Int J Exp Pathol 1995;76:317-330.
13. Rappaport JM, Bhatt SM, Kimura RS, et al. Electron microscopic temporal bone histopathology in experimental pneumococcal meningitis. Ann Otol Rhinol Laryngol 1999;108: 537-547.
14. Konkol RJ, Chapman L, Breese GR, et al. Haemophilus influenzae meningitis in the rat: behavioral, electrophysiological, and biochemical consequences. Ann Neurol 1987;21:353-360.
15. Kastenbauer S, Klein M, Koedel U, Pfister HW. Reactive nitrogen species contribute to blood-labyrinth barrier disruption in suppurative labyrinthitis complicating experimental pneumococcal meningitis in the rat. Brain Res 2001;904:208-217.
16. Klein M, Koedel U, Kastenbauer S, Pfister HW. Morphological correlates of acute and permanent hearing loss during experimental pneumococcal meningitis. Brain Pathol 2003;13:1-10.
17. Nabili V, Brodie HA, Neverov NI, Tinling SP. Chronology of labyrinthitis ossificans induced by Streptococcus pneumoniae meningitis. Laryngoscope 1999;109:931-935.
18. Koedel U, Winkler F, Angele B, et al. Role of caspase-1 in experimental pneumococcal meningitis: evidence from pharmacologic caspase inhibition and caspase-1-deficient mice. Ann Neurol 2002;51:319-329.
19. Koedel U, Bernatowicz A, Paul R, et al. Experimental pneumococcal meningitis: cerebrovascular alterations, brain edema, and meningeal inflammation are linked to the production of nitric oxide. Ann Neurol 1995;37:313-323.
20. Paul R, Lorenzl S, Koedel U, et al. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann Neurol 1998;44:592-600.
21. Kastenbauer S, Koedel U, Becker B, Pfister HW. Pneumococcal meningitis in the rat: evaluation of peroxynitrite scavengers for adjunctive therapy. Eur J Pharmacol 2002;449:177-181.
22. Koedel U, Pfister HW. Protective effect of the antioxidant N-acetyl-L-cysteine in pneumococcal meningitis in the rat. Neurosci Lett 1997;225:33-36.
23. Arteel GE, Briviba K, Sies H. Protection against peroxynitrite. FEBS Lett 1999;445:226-230.
24. Gauuan PJ, Trova MP, Gregor-Boros L, et al. Superoxide dismutase mimetics: synthesis and structure-activity relationship study of MnTBAP analogues. Bioorg Med Chem 2002;10: 3013-3021.
25. Kastenbauer S, Koedel U, Pfister HW. Oxidative brain damage by peroxynitrite in bacterial meningitis: a target for adjunctive therapy? Curr Med Chem Cent Nerv Syst Agents 2002;2: 109-127.
26. Auer M, Pfister LA, Leppert D, et al. Effects of clinically used antioxidants in experimental pneumococcal meningitis. J Infect Dis 2000;182:347-350.
27. Christen S, Schaper M, Lykkesfeldt J, et al. Oxidative stress in brain during experimental bacterial meningitis: differential effects of alpha-phenyl-tert-butyl nitrone and N-acetylcysteine treatment. Free Radic Biol Med 2001;31:754-762.
28. Schaper M, Gergely S, Lykkesfeldt J, et al. Cerebral vasculature is the major target of oxidative protein alterations in bacterial meningitis. J Neuropathol Exp Neurol 2002;61:605-613.
29. Gopen Q, Rosowski JJ, Merchant SN. Anatomy of the normal human cochlear aqueduct with functional implications. Hear Res 1997;107:9-22.
30. Kesser BW, Hashisaki GT, Spindel JH, et al. Time course of hearing loss in an animal model of pneumococcal meningitis. Otolaryngol Head Neck Surg 1999;120:628-637.
31. Kay R. The site of the lesion causing hearing loss in bacterial meningitis: a study of experimental streptococcal meningitis in guinea-pigs. Neuropathol Appl Neurobiol 1991;17:485-493.
32. Dichgans M, Jager L, Mayer T, et al. Bacterial meningitis in adults: demonstration of inner ear involvement using high-resolution MRI. Neurology 1999;52:1003-1009.
33. Anniko M, Wroblewski R. Ionic environment of cochlear hair cells. Hear Res 1986;22:279-293.
34. Guerra-Romero L, Tureen JH, Fournier MA, et al. Amino acids in cerebrospinal and brain interstitial fluid in experimental pneumococcal meningitis. Pediatr Res 1993;33:510-513.
35. Leib SL, Kim YS, Ferriero DM, Tauber MG. Neuroprotective effect of excitatory amino acid antagonist kynurenic acid in experimental bacterial meningitis. J Infect Dis 1996;173: 166-171.
36. Paparella MM, Sugiura S. The pathology of suppurative labyrinthitis. Ann Otol Rhinol Laryngol 1967;76:554-586.
37. Winter AJ, Marwick S, Osborne M, et al. Ultrastructural damage to the organ of corti during acute experimental Escherichia coli and pneumococcal meningitis in guinea pigs. Acta Otolaryngol 1996;116:401-407.
38. Takeno S, Wake M, Mount RJ, Harrison RV. Degeneration of spiral ganglion cells in the chinchilla after inner hair cell loss induced by carboplatin. Audiol Neurootol 1998;3:281-290.
39. Webster M, Webster DB. Spiral ganglion neuron loss following organ of Corti loss: a quantitative study. Brain Res 1981;212: 17-30.